1 / 1

A PROSPECTIVE RANDOMIZED PHASE I/II STUDY OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE (RMPT) FOR RELAPSED/REF

Grade 1-2. Grade 3-4. Infective. Fatigue. Cardiac. Thrombosis. 0. 10. 20. 30. 40. 50. % Patients. A PROSPECTIVE RANDOMIZED PHASE I/II STUDY OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE (RMPT) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS.

mykelti
Download Presentation

A PROSPECTIVE RANDOMIZED PHASE I/II STUDY OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE (RMPT) FOR RELAPSED/REF

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Grade 1-2 Grade 3-4 Infective Fatigue Cardiac Thrombosis 0 10 20 30 40 50 % Patients A PROSPECTIVE RANDOMIZED PHASE I/II STUDY OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE (RMPT) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS Federica Cavallo MD (1),Alessandra Larocca MD (1), Maria Teresa Petrucci MD (2), Vincenzo Federico MD (2), Antonietta Pia Falcone MD (3), Grazia Sanpaolo MD (3), Letizia Canepa MD (4), Monica Crugnola MD (5), Mario Boccadoro MD (1) and Antonio Palumbo MD (1). (1) Divisione di Ematologia dell'Università di Torino – A.O.U. San Giovanni Battista, Torino; (2) Dipartimento di Biotecnologie e Ematologia, Università La Sapienza, Roma; (3) U.O. Ematologia e Trapianto, IRCSS Casa Sollievo della Sofferenza, San Giovanni Rotondo; (4) Clinica Ematologica, Università di Genova, Ospedale S. Martino, Genova; (5) Università degli Studi di Parma, Cattedra e U.O. Ematologia e Trapianti Midollo, Parma. HEMATOLOGIC TOXICITYGrade 3-4 Adverse Events PFS ACCORDING TO PRIOR LINE OF TREATMENT BACKGROUND AND RATIONALE TREATMENT SCHEDULE Proportion ofpatients NON-HEMATOLOGIC TOXICITYGrade 1-2 and 3-4 Adverse Events Months PATIENT CHARACTERISTICS PFS THALIDOMIDE 50 mg versus 100 mg RATIONALE Proportion ofpatients PROGRESSION FREE SURVIVAL RMPT in Advanced MMMivPT in Advanced MM Months AIMS PFS ACCORDING TO RESPONSE Proportion ofpatients Proportion ofpatients Months TREATMENT SCHEDULE OVERALL SURVIVAL Months RESPONSE RATE AND THALIDOMIDE DOSE CONCLUSIONS Proportion ofpatients Months

More Related